Are there differences in type, dosage, and method of administration for the systemic steroids in IBD treatment?
Teshima
Christopher
C
Center of Excellence for Gastrointestinal Inflammation and Immunity Research (CEGIIR), Division of Gastroenterology, University of Alberta, Alberta, Canada.
Fedorak
Richard N
RN
D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000473:pathology; D003424:Crohn Disease / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D008775:Methylprednisolone / Q000008:administration & dosage / Q000009:adverse effects; D011239:Prednisolone / Q000008:administration & dosage / Q000009:adverse effects; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction / Q000379:methods; D055502:Secondary Prevention; D012720:Severity of Illness Index
D005938:Glucocorticoids; D011239:Prednisolone; D011241:Prednisone; D008775:Methylprednisolone